TAG:
ehi
Spectrum Lab Network Expands Into Tennessee
By Robert Michel | From the Volume XI No. 3 – February 23, 2004 Issue
CEO SUMMARY: During the past four years, this energized hospital laboratory joint venture has posted significant growth in its laboratory outreach program. One notable accomplishment has been the effective deployment and use of Web browser-based lab test orders and results reporting with …
LAB-Interlink Hangs On Despite Financial Woes
By Robert Michel | From the Volume XI No. 2 – February 2, 2004 Issue
CEO SUMMARY: It’s an uphill struggle at LAB-Interlink, based in Omaha, Nebraska. Short of funds, staffed with only a few employees, and urgently seeking capital, the company has so far managed to avoid filing for protection under bankruptcy laws. It is an unwelcome turn of events, since…
Free of IMPATH, Tamtron Ready For A New Future
By Robert Michel | From the Volume XI No. 2 – February 2, 2004 Issue
CEO SUMMARY: Tamtron’s fortunes look much brighter with its acquisition by IMPAC Medical Systems, Inc., a healthcare information vendor with existing products for radiation oncology, medical oncology, and urology. IMPAC’s strategy is to create a “total solution” for oncology. That…
RFP Secrets To Use When Buying Molecular Tests
By Robert Michel | From the Volume XI No. 1 – January 12, 2004 Issue
CEO SUMMARY: It often takes two to four years before payer coverage and reimbursement become stable. During that time, NorDx Laboratories wants the vendors who sell it new molecular assays to have some “skin in the game.” It accomplishes this by negotiating contracts that link the con…
2003’s Big Lab Stories Reflect Health Trends
By Robert Michel | From the Volume X No. 17 – December 22, 2003 Issue
CEO SUMMARY: At a minimum, 2003 proved to be a year of relative stability for the laboratory industry, as demonstrated by THE DARK REPORT’S “Ten Biggest Lab Stories of 2003.” The year was free of industry-wide crises and scan- dals. That allowed most laboratory administrators and pa…
Who’s Buying Labs? Activity Shifts Down
By Robert Michel | From the Volume X No. 17 – December 22, 2003 Issue
CEO SUMMARY: As the number of independent clinical laboratories dwindles, most remaining owners seem content to continue building their business—at least until a buyer makes them an offer “they can’t refuse.” Acquisitions of pathology group practices were also few in number during…
Market Demand for Pathologists Shifts Toward Specialization
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
CEO SUMMARY: Unlike the slack employment market for pathologists seen during the 1990s, there is strong demand for pathologists in this decade. Private pathology group practices now face competition for the best pathology talent. That’s because public lab companies are regularly in the …
Chipping Away at Laboratory Reimbursement
By Robert Michel | From the Volume X No. 14 – October 20, 2003 Issue
PROPOSED NEW MEDICARE RULES by the Office of the Investigator General (OIG) dealing with “discriminatory billing practices” and “usual charges” should be seen as part of a larger trend. The government doesn’t have the money to pay for Medicare and Medicaid. Thus, it is expl…
Two Blood Brothers Ramp Up Marketing of New Lab Assays
By Robert Michel | From the Volume X No. 14 – October 20, 2003 Issue
GROWTH IN SPECIMEN VOLUME and revenues is the major challenge at the nation’s two largest laboratory corporations. How Laboratory Corporation of America and Quest Diagnostics Incorporated solve this problem will affect and influence every remaining clinical labora…
“September 29, 2003 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume X No. 13 – September 29, 2003 Issue
There was cautious optimism among lab industry leaders lobbying Congress to stop the proposed 20% co- payment for Part B laboratory testing services. It seems that, over the summer break, Iowa Senator Charles Grassley got a lesson in grass roots lobbying. At a number of town meetings, irate seniors s…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized